相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Upregulation of CD109 Promotes the Epithelial-to-Mesenchymal Transition and Stemness Properties of Lung Adenocarcinomas via Activation of the Hippo-YAP Signaling
Kang-Yun Lee et al.
CELLS (2021)
Effect of N6-Methyladenosine Regulators on Progression and Prognosis of Triple-Negative Breast Cancer
Shanshan Wang et al.
FRONTIERS IN GENETICS (2021)
The Role of Protein Arginine Methylation as Post-Translational Modification on Actin Cytoskeletal Components in Neuronal Structure and Function
Britta Qualmann et al.
CELLS (2021)
Prognostic Value of a Glycolytic Signature and Its Regulation by Y-Box-Binding Protein 1 in Triple-Negative Breast Cancer
Yi-Wen Lai et al.
CELLS (2021)
The methyltransferase PRMT1 regulates γ-globin translation
Ying Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2021)
PARP and PARG inhibitors in cancer treatment
Dea Slade
GENES & DEVELOPMENT (2020)
PRMT1 Is Recruited via DNA-PK to Chromatin Where It Sustains the Senescence-Associated Secretory Phenotype in Response to Cisplatin
Daniele Musiani et al.
CELL REPORTS (2020)
PRMT1 promotes neuroblastoma cell survival through ATF5
Zhong-Yan Hua et al.
ONCOGENESIS (2020)
FoxM1-dependent and fatty acid oxidation-mediated ROS modulation is a cell-intrinsic drug resistance mechanism in cancer stem-like cells
Hae-Ji Choi et al.
REDOX BIOLOGY (2020)
Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status
Man Yee Keung et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Methylation of HSP70 Orchestrates Its Binding to and Stabilization of BCL2 mRNA and Renders Pancreatic Cancer Cells Resistant to Therapeutics
Liang Wang et al.
CANCER RESEARCH (2020)
PRMT1 Is Critical for the Transcriptional Activity and the Stability of the Progesterone Receptor
Lucie Malbeteau et al.
ISCIENCE (2020)
PRMT1-dependent methylation of BRCA1 contributes to the epigenetic defense of breast cancer cells against ionizing radiation
Maria F. Montenegro et al.
SCIENTIFIC REPORTS (2020)
Triple-negative breast cancer therapy: Current and future perspectives (Review)
Kwang-Ai Won et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2020)
Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies
Gagan K. Gupta et al.
CANCERS (2020)
New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer
Ye Han et al.
FRONTIERS IN ONCOLOGY (2020)
PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers
Patrick G. Pilie et al.
CLINICAL CANCER RESEARCH (2019)
The arginine methyltransferase PRMT1 regulates IGF-1 signaling in breast cancer
Ali Choucair et al.
ONCOGENE (2019)
Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment
Ana C. Garrido-Castro et al.
CANCER DISCOVERY (2019)
MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer
Jingyan Yi et al.
EBIOMEDICINE (2019)
Methylation of C/EBPa by PRMT1 Inhibits Its Tumor-Suppressive Function in Breast Cancer
Li-Ming Liu et al.
CANCER RESEARCH (2019)
Delivery of Anti-miRNA for Triple-Negative Breast Cancer Therapy Using RNA Nanoparticles Targeting Stem Cell Marker CD133
Hongran Yin et al.
MOLECULAR THERAPY (2019)
PRMT1 regulates the tumour-initiating properties of esophageal squamous cell carcinoma through histone H4 arginine methylation coupled with transcriptional activation
Yue Zhao et al.
CELL DEATH & DISEASE (2019)
Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma
Jian-Fang Ning et al.
NATURE COMMUNICATIONS (2019)
Role of protein arginine methyltransferase 5 in group 3 (MYC-driven) Medulloblastoma
Nagendra K. Chaturvedi et al.
BMC CANCER (2019)
PARP Inhibition in Cancer: An Update on Clinical Development
Esha Sachdev et al.
TARGETED ONCOLOGY (2019)
The Protein Arginine Methyltransferases 1 and 5 affect Myc properties in glioblastoma stem cells
Annarita Favia et al.
SCIENTIFIC REPORTS (2019)
PRMT1 Promoted HCC Growth and Metastasis In Vitro and In Vivo via Activating the STAT3 Signalling Pathway
Xiu-Ping Zhang et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2018)
PARP Inhibitors in Ovarian Cancer
Gloria Mittica et al.
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY (2018)
PRMT5 Regulates DNA Repair by Controlling the Alternative Splicing of Histone-Modifying Enzymes
Pierre-Jacques Hamard et al.
CELL REPORTS (2018)
Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors
Isabella Faraoni et al.
CANCERS (2018)
Arginine methylation regulates c-Myc-dependent transcription by altering promoter recruitment of the acetyltransferase p300
Irina Tikhanovich et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
PRMT1-Mediated Translation Regulation Is a Crucial Vulnerability of Cancer
Jessie Hao-Ru Hsu et al.
CANCER RESEARCH (2017)
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
Giampaolo Bianchini et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
RespondR signature to predict potential alternative therapies for taxane resistant triple-negative breast cancer patients.
Steven Allen Buechler et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response
Hsin-Wei Liao et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond
Nicola J. Curtin et al.
MOLECULAR ASPECTS OF MEDICINE (2013)
Protein arginine methyltransferases and cancer
Yanzhong Yang et al.
NATURE REVIEWS CANCER (2013)
Two sides of the Myc-induced DNA damage response: from tumor suppression to tumor maintenance
Stefano Campaner et al.
CELL DIVISION (2012)
c-Myc Suppression of DNA Double-strand Break Repair
Zhaozhong Li et al.
NEOPLASIA (2012)
The role of PARP in DNA repair and its therapeutic exploitation
M. Javle et al.
BRITISH JOURNAL OF CANCER (2011)
Tumor Cell Kill by c-MYC Depletion: Role of MYC-Regulated Genes that Control DNA Double-Strand Break Repair
Kaisa R. Luoto et al.
CANCER RESEARCH (2010)
Triple-negative breast cancer: disease entity or title of convenience?
Lisa Carey et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Poly(ADP-ribose) polymerase (PARP-1) in homologous recombination and as a target for cancer therapy
T Helleday et al.
CELL CYCLE (2005)
分享论文
